Bottom line
SHPCX vs PBE: the short answer
SHPCX (Health & Biotechnology Portfolio) and PBE (Invesco Biotechnology & Genome ETF) are both mutual funds.
PBE is cheaper at 0.59% vs 3.6% — a difference of $301 a year per $10,000 invested.
Over five years, SHPCX returned +3.7% a year vs +3.4% for PBE (reporting dates differ).
Updated Nov 19, 2026
SHPCX vs PBE side by side
| SHPCX | PBE | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Saratoga Advantage | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 3.6% | 0.59% |
| Annual cost per $10k | $360 | $59 |
| 10-yr cost on $10k (prospectus) | $3,862 | $738 |
| Max front load | 0% | None |
| 12b-1 fee | — | — |
| 1-yr return | −1.3% | +24.7% |
| 5-yr return (annualized) | +3.7% | +3.4% |
| 10-yr return (annualized) | +4.1% | +5.2% |
| Best quarter | +15.0% | +25.3% |
| Worst quarter | −13.0% | −24.3% |
| Net assets (fund) | $10.5M | $281.9M |
| Number of holdings | 29 | 33 |
| Portfolio turnover | 22% | 103% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SHPCX | PBE | Difference |
|---|---|---|---|
| 2024 | −0.3% | +1.1% | −1.4% |
| 2023 | −0.9% | +3.7% | −4.6% |
| 2022 | +1.4% | −10.8% | +12.2% |
| 2021 | +16.0% | +1.6% | +14.5% |
| 2020 | +3.0% | +25.5% | −22.5% |
| 2019 | +15.4% | +18.3% | −2.8% |
| 2018 | −6.0% | +0.2% | −6.2% |
| 2017 | +11.3% | +22.4% | −11.2% |
| 2016 | −2.5% | −23.0% | +20.5% |
| 2015 | +6.3% | +2.0% | +4.2% |
Source: Fund prospectus bar charts
Holdings overlap
7 of SHPCX's top 25 holdings also appear in PBE's top 25.
| Holding | SHPCX | PBE |
|---|---|---|
| United Therapeutics Corp | 6.17% | 4.08% |
| Amgen Inc | 5.04% | 5.22% |
| Exelixis Inc | 4.55% | 2.64% |
| Gilead Sciences Inc | 3.94% | 4.43% |
| Regeneron Pharmaceuticals Inc | 3.93% | 5.47% |
| Vertex Pharmaceuticals Inc | 3.36% | 4.99% |
| Incyte Corp | 2.89% | 3.06% |
Source: SEC Form N-PORT
SHPCX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between SHPCX and PBE?
Which is cheaper, SHPCX or PBE?
Should I own both SHPCX and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.